Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease
Authors
Keywords
-
Journal
Annals of Clinical and Translational Neurology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-01-19
DOI
10.1002/acn3.51300
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CaV1.3 L-Type Calcium Channels Increase the Vulnerability of Substantia Nigra Dopaminergic Neurons in MPTP Mouse Model of Parkinson’s Disease
- (2020) Aditi Verma et al. Frontiers in Aging Neuroscience
- A Clinical Trial of Isradipine: What Went Wrong?
- (2020) Baijayanta Maiti et al. ANNALS OF INTERNAL MEDICINE
- Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
- (2020) Rob M A de Bie et al. LANCET NEUROLOGY
- The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson's Disease
- (2019) Birgit Liss et al. Annual Review of Pharmacology and Toxicology
- Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress
- (2018) Jaime N. Guzman et al. JOURNAL OF CLINICAL INVESTIGATION
- The Emerging Evidence of the Parkinson Pandemic
- (2018) E. Ray Dorsey et al. Journal of Parkinsons Disease
- Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease
- (2017) D. James Surmeier et al. EXPERIMENTAL NEUROLOGY
- Selective neuronal vulnerability in Parkinson disease
- (2017) D. James Surmeier et al. NATURE REVIEWS NEUROSCIENCE
- Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice
- (2017) Qi-Min Wang et al. Oncotarget
- Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
- (2016) Tanya Simuni et al. Annals of Clinical and Translational Neurology
- Parkinson's disease
- (2015) Lorraine V Kalia et al. LANCET
- Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis
- (2015) Yakun Lang et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase
- (2014) Javier Sanchez-Padilla et al. NATURE NEUROSCIENCE
- Pharmacokinetic properties of isradipine after single-dose and multiple-dose oral administration in Chinese volunteers: a randomized, open-label, parallel-group phase I study
- (2013) Yanran Wang et al. BIOMEDICAL CHROMATOGRAPHY
- Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins
- (2013) Michael J. Hurley et al. BRAIN
- Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
- (2013) MOVEMENT DISORDERS
- Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease
- (2012) Joshua A Goldberg et al. NATURE NEUROSCIENCE
- Age-Related Changes in Pharmacokinetics
- (2011) Shaojun Shi et al. CURRENT DRUG METABOLISM
- Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta-analysis of randomized trials
- (2011) Harikrishna Makani et al. JOURNAL OF HYPERTENSION
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
- (2011) E. Ilijic et al. NEUROBIOLOGY OF DISEASE
- L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease
- (2010) Thimmappa S. Anekonda et al. NEUROBIOLOGY OF DISEASE
- Cav1.3 Channel Voltage Dependence, Not Ca2+ Selectivity, Drives Pacemaker Activity and Amplifies Bursts in Nigral Dopamine Neurons
- (2009) I. Putzier et al. JOURNAL OF NEUROSCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started